Pulmonary Fibrosis Pipeline constitutes 110+ key companies continuously working towards developing 140+ Pulmonary Fibrosis treatment therapies, analyzes DelveInsight.
Pulmonary Fibrosis Overview:
Pulmonary fibrosis (PF) is a chronic, progressive lung disease characterized by the thickening and scarring (fibrosis) of lung tissue, particularly the interstitium, the area surrounding the air sacs (alveoli). This scarring leads to stiffening of the lungs, reducing their ability to transport oxygen into the bloodstream and making it increasingly difficult to breathe.
Request for a detailed insights report on Pulmonary Fibrosis pipeline insights
"Pulmonary Fibrosis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Pulmonary Fibrosis Therapeutics Market.
Key Takeaways from the Pulmonary Fibrosis Pipeline Report
-
DelveInsight’s Pulmonary Fibrosis pipeline report depicts a robust space with 110+ active players working to develop 140+ pipeline therapies for Pulmonary Fibrosis treatment.
-
On October 7, 2025, the JASCAYD® (active ingredient: nerandomilast) tablets were approved by the Food & Drug Administration (FDA) for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
-
Key Pulmonary Fibrosis companies such as Wuhan Optics Valley Vcanbiopharma Co., Ltd. Sarepta Therapeutics, Avalyn Pharma, PureTech Health, Bristol-Myers Squibb, and others are evaluating new drugs for Pulmonary Fibrosis to improve the treatment landscape.
-
Promising Pulmonary Fibrosis pipeline therapies in various stages of development include BMS-986278, LYT-100, AP01, ARO-MMP7, VUM02, and others.
Pulmonary Fibrosis Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the key companies that are developing therapies in the Pulmonary Fibrosis Market.
-
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Fibrosis treatment.
-
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Pulmonary Fibrosis market.
Download our free sample page report on Pulmonary Fibrosis pipeline insights
Pulmonary Fibrosis Emerging Drugs
-
BMS-986278: Bristol-Myers Squibb
BMS-986278 is an investigational, first-in-class oral small molecule that acts as a lysophosphatidic acid receptor 1 (LPA1) antagonist, being developed as a novel antifibrotic therapy for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). Elevated LPA levels and LPA1 activation are known to play key roles in the development of pulmonary fibrosis. BMS-986278 functions as a potent and comprehensive blocker of LPA1-mediated Gi, Gq, G12, and β-arrestin signaling pathways in both engineered human cell systems and primary human lung fibroblasts. The therapy is currently in Phase III clinical trials for pulmonary fibrosis.
-
LYT-100: PureTech Health
LYT-100 (deupirfenidone) is being developed for the treatment of idiopathic pulmonary fibrosis (IPF), a rare, progressive, and life-threatening lung disease. As a deuterated version of pirfenidone, LYT-100 is designed to preserve the proven therapeutic benefits of pirfenidone while offering a distinct and improved pharmacokinetic (PK) profile. Across several clinical trials, the drug has shown enhanced tolerability, potentially supporting longer treatment duration and improved disease management. LYT-100 is currently in Phase II clinical trials for pulmonary fibrosis.
-
AP01: Avalyn Pharma
AP01, developed by Avalyn Pharma, is a novel inhaled formulation of pirfenidone intended for the treatment of pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). This inhaled version is designed to improve therapeutic effectiveness and reduce systemic side effects commonly seen with oral pirfenidone. The candidate is currently in Phase II clinical trials for pulmonary fibrosis.
-
ARO-MMP7: Sarepta Therapeutics
ARO-MMP7 is an investigational RNA interference (RNAi) therapy developed by Arrowhead Pharmaceuticals for the treatment of idiopathic pulmonary fibrosis (IPF). It works by silencing the expression of matrix metalloproteinase 7 (MMP7), a protein associated with inflammation and fibrotic tissue remodeling in the lungs. The candidate is currently being evaluated in Phase I/II clinical trials for pulmonary fibrosis.
Pulmonary Fibrosis Companies
Over 110 key companies are actively developing therapies for Pulmonary Fibrosis. Among them, Bristol-Myers Squibb has a drug candidate that has reached the most advanced stage of development—Phase III clinical trials.
DelveInsight’s report covers around 75+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Pulmonary Fibrosis Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Pulmonary Fibrosis Therapies and Key Companies: Pulmonary Fibrosis Clinical Trials and advancements
Pulmonary Fibrosis Pipeline Therapeutic Assessment
• Pulmonary Fibrosis Assessment by Product Type
• Pulmonary Fibrosis By Stage
• Pulmonary Fibrosis Assessment by Route of Administration
• Pulmonary Fibrosis Assessment by Molecule Type
Download Pulmonary Fibrosis Sample report to know in detail about the Pulmonary Fibrosis treatment market @ Pulmonary Fibrosis Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Pulmonary Fibrosis Current Treatment Patterns
4. Pulmonary Fibrosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Pulmonary Fibrosis Late-Stage Products (Phase-III)
7. Pulmonary Fibrosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Pulmonary Fibrosis Discontinued Products
13. Pulmonary Fibrosis Product Profiles
14. Pulmonary Fibrosis Key Companies
15. Pulmonary Fibrosis Key Products
16. Dormant and Discontinued Products
17. Pulmonary Fibrosis Unmet Needs
18. Pulmonary Fibrosis Future Perspectives
19. Pulmonary Fibrosis Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Pulmonary Fibrosis Pipeline Reports Offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
